Compensation award — excluded from discretionary-purchase analysis.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
View the official recordSEC Form 4 — Statement of Changes in Beneficial OwnershipAll the details
Dates, kept separate
Transaction date
Dec 31, 2025
Reporting period
Not applicable
Filed with the SEC
Jan 5, 2026
DirectorGrant / award
Context
Classification
grant award
Code A — grant or award
Planned / mechanical clue
Footnote references dividend reinvestment
Only flagged when a footnote says so; never inferred
Source receipt
Record ID
0001385262-26-000002
Filed / recorded
Jan 5, 2026, 11:46 PM UTC
Added to OQRO
Oct 2, 2026, 12:26 PM UTC
Parser
form4-xml-v1
Data quality
Verified: identifiers matched exactly
Issuer
ABBOTT LABORATORIES
Issuer CIK
1800
Ticker
ABT
Reporting person
John G Stratton
Relationship
Director
Security
Stock Equivalent Units
Table
Derivative (Table II)
Transaction date
Dec 31, 2025
Transaction code
A
Shares / units
313
Price per share
$125.29
Acquired / disposed
Acquired (A)
Shares owned after
13,034
Ownership form
Direct
Amendment
No
Footnotes from the filing
Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott shares.
Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.
The boss of Abbott Laboratories spent $2.01M of their very own money to buy Abbott Laboratories shares. 1 other person at Abbott Laboratories bought some too, in the same month. Their pile of Abbott Laboratories shares grew by 10%.
Congress trade
Congress trade